Glen Kwon, professor, in the Pharmaceutical Sciences Division, co-founder and chief scientific officer of Co-D Therapeutics, a University of Wisconsin–Madison spinoff, is developing a three-drug cocktail to battle a wide range of cancers. The first target for Co-D is angiosarcoma, a rare and lethal cancer that arises from blood vessels. Read the full story. Kwon has been working on new drug carriers and combination cancer treatments for more than 20 years. His pharmaceutical research is in the area of nanomedicine that focuses on polymeric assemblies for drug delivery, non-viral gene delivery and optical imaging. Within this context, his lab group is interested in fundamental pharmaceutical concepts in drug solubilization, controlled release and drug targeting. These insights into polymeric assemblies allow exploration of therapeutic strategies that involve novel nanomedicines that are bio-responsive, synergistic and theranostic, aiming for progress against lung, breast and ovarian cancers and also systemic fungal diseases.